MSD receives FDA approval for its Keytruda combo for the therapy of ovarian most cancers
MSD has acquired approval from the U.S. Meals and Drug Administration (FDA) for Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), together with paclitaxel, with or with out bevacizumab, for the therapy of ovarian most cancers.
The therapies are authorised as second- or third-line therapy for adults with platinum-resistant ovarian, fallopian tube or main peritoneal carcinoma whose tumors categorical programmed loss of life ligand 1 (PD-L1) (mixed optimistic rating). [CPS] ≥1), as decided by an FDA-approved check.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra data
The approvals comply with information from the Part III KEYNOTE-B96 trial (ENGOT-ov65), which had been offered on the 2025 Congress of the European Society for Medical Oncology (ESMO).
The outcomes confirmed statistically important enhancements in progression-free survival and general survival in comparison with placebo plus paclitaxel with or with out bevacizumab in sufferers whose tumors categorical PD-L1 (CPS ≥1).
The approval of Keytruda Qlex for its indications is supported by information from well-controlled research of Keytruda and extra outcomes from MK-3475A-D77, which in contrast the efficacy, security and pharmacokinetic profiles of Keytruda Qlex and Keytruda.
Dr. Gursel Aktan, vice chairman of medical improvement at MSD Analysis Laboratories, mentioned: “Traditionally, the prognosis has been poor for sufferers with platinum-resistant relapsed ovarian most cancers, who’ve restricted therapy choices that may cut back the chance of illness development or loss of life. These approvals mark an vital second for the ovarian most cancers neighborhood and mirror years of centered investments in Keytruda.
“The introduction of the primary PD-1 inhibitors for platinum-resistant ovarian most cancers means we’re increasing choices for sufferers going through this illness. It additionally reinforces our dedication to advancing revolutionary therapies and improved outcomes in girls’s cancers, the place the necessity is biggest.”
In June 2025, MSD acquired FDA approval for its anti-PD-1 remedy, Keytruda, for adults with resectable domestically superior squamous cell carcinoma of the top and neck (HNSCC).
